WEST LAFAYETTE, Ind., Nov. 5, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced financial results for the third quarter ending Sept. 30, 2013, and provided a business update.
Help employers find you! Check out all the jobs and post your resume.
